425: Waters Corporation and BD Announce Strategic Combination of Biosciences and Diagnostic Solutions Business

Waters Corporation and Becton, Dickinson and Company (BD) announced their intent to combine BD's Biosciences and Diagnostic Solutions business with Waters, aiming to create a leading life science and diagnostics company focused on regulated, high-volume testing.

Summary

• Waters Corporation and Becton, Dickinson and Company (BD) intend to combine BD's Biosciences and Diagnostic Solutions business with Waters Corporation.
• The transaction aims to create a life science and diagnostics leader focused on regulated, high-volume testing.
• The combination is expected to diversify Waters' portfolio, increase recurring revenue, and double its addressable market to $40 billion.
• It accelerates Waters' strategy into fast-growing adjacencies including bioseparations, bioanalytical characterization, and multiplex diagnostics.
• The transaction is anticipated to create an industry-leading financial outlook with enhanced growth, improved margins, and is expected to be accretive to adjusted EPS in the first year post-closing.
• For BD, this represents a significant step towards becoming a pure-play medical technology company, focusing on areas like biologic drug delivery, connected care, healthcare automation, and chronic disease solutions.
• The closing of the transaction is expected around the end of the first quarter of calendar year 2026.
• Both companies will continue to operate separately and independently until the close, with BD remaining focused on its BD2025 strategy.

Sentiment

Score: 9

Explanation: The communication is overwhelmingly positive, highlighting significant strategic benefits, market expansion, and financial improvements for both companies and their shareholders. The tone is confident and forward-looking, emphasizing value creation and leadership in key sectors.

Positives

• Diversification of Waters' portfolio, increasing recurring revenue.
• Doubles Waters' addressable market to $40 billion, focusing on regulated, high-volume end-markets.
• Accelerates Waters' expansion into fast-growing adjacencies: bioseparations, bioanalytical characterization, and multiplex diagnostics.
• Creates an industry-leading financial outlook with enhanced growth and improved margins.
• Expected to be accretive to adjusted EPS in the first year post-closing.
• Transforms BD into a pure-play medical technology company, focusing on high-growth healthcare trends.
• Combines complementary strengths to advance human health and well-being in ways neither company could achieve individually.

Risks

• One or more closing conditions, including regulatory approvals, may not be satisfied or waived on a timely basis or at all.
• A governmental entity may prohibit, delay, or refuse to grant approval, or require conditions, limitations, or restrictions.
• Required approval by Waters' stockholders may not be obtained.
• The proposed transaction may not be completed on the expected terms, timeframe, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Failure to realize the anticipated benefits, including synergies, due to delays in completion or integration difficulties.
• Inability of the combined company to implement its business strategy.
• Difficulties and delays in the combined company achieving revenue and cost synergies.
• Inability of the combined company to retain and hire key personnel.
• Occurrence of any event that could give rise to termination of the proposed transaction.
• Stockholder litigation or other litigation, settlements, or investigations may affect timing, occurrence, or result in significant costs.
• Evolving legal, regulatory, and tax regimes.
• Changes in general economic and/or industry-specific conditions or volatility from tariffs.
• Actions by third parties, including government agencies.
• The anticipated tax treatment of the proposed transaction may not be obtained.
• Greater than expected difficulty in separating SpinCo's business from other BD businesses.
• Disruption of management time from ongoing business operations due to the pendency of the transaction.
• Other effects of the transaction's pendency on relationships with employees, customers, suppliers, or other counterparties.

Future Outlook

The combined company aims to be a leading life science and diagnostics entity focused on regulated, high-volume testing, expanding into high-value, long-term growth areas like bioseparations, bioanalytical characterization, and multiplex diagnostics. BD will transition to a pure-play medical technology company, focusing on biologic drug delivery, connected care, healthcare automation, and chronic disease solutions. Both companies anticipate significant value creation for shareholders, customers, partners, and associates.

Management Comments

• Thomas Polen (BD): "I am thrilled about our intent to combine our Biosciences and Diagnostic Solutions business with Waters. This transaction will be combining the complementary strengths of both Waters and BD to create a life science and diagnostics leader focused on regulated, high-volume testing."
• Thomas Polen (BD): "Waters is the right fit for these great businesses and for our teams – both for the substantial value this will create for shareholders and because Waters is a great place for our teams to make an even more profound impact on global healthcare."
• Udit Batra (Waters): "The diversification in the portfolio increases our recurring revenue and doubles our addressable market to $40 billion, while keeping us in regulated, high-volume end-markets."
• Udit Batra (Waters): "This transaction creates an industry-leading financial outlook with enhanced growth, improved margins, and is expected to be accretive to adjusted EPS in the first year post-closing."
• Thomas Polen (BD): "This transaction also represents a significant step forward in making BD a pure-play medical technology company at the forefront of healthcares biggest growth trends."
• Udit Batra (Waters): "As we move toward closing, which we expect to be around the end of first quarter of calendar year 2026, we will begin integration planning. We are committed to communicating updates."

Industry Context

This announcement signifies a strategic realignment within the life sciences and medical technology sectors. Waters Corporation is expanding its footprint into high-growth adjacencies like bioseparations and multiplex diagnostics, leveraging BD's established biosciences and diagnostic solutions. Concurrently, BD is sharpening its focus to become a pure-play medical technology company, divesting a segment to concentrate on areas like biologic drug delivery and connected care. This reflects a broader industry trend towards specialization, strategic partnerships, and targeting high-demand, regulated markets to drive growth and efficiency.

Comparison to Industry Standards

• The document states the combined entity will have an "industry-leading financial outlook" and "best-in-class products positioned in large and attractive end-markets," but does not provide specific comparable companies, projects, or results to benchmark against.

Legal Proceedings

• Potential stockholder litigation in connection with the proposed transaction or other litigation, settlements, or investigations may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• Shareholders: Expected to see substantial value creation and adjusted EPS accretion.
• Customers: Will benefit from unparalleled value with best-in-class products and pioneering science.
• Associates/Employees: Will join a company that deeply values innovation, execution, and excellence, with significant new opportunities.
• Partners: Expected to benefit from the combined entity's enhanced capabilities and market position.

Next Steps

• Begin integration planning as the companies move towards closing.
• Continue communicating updates regarding the transaction.
• Waters and BD will continue to operate separately and independently until the transaction closes.
• BD will remain focused on executing its BD2025 strategy, driving growth, commercial excellence, and new innovation.

Key Dates

Recommendation

Keywords

Waters Corporation, Becton Dickinson, BD, Augusta SpinCo, business combination, spin-off, life science, diagnostics, biosciences, medical technology, bioseparations, bioanalytical characterization, multiplex diagnostics, regulated testing, merger, acquisition